BioVacSafe is a consortium of vaccine manufacturers together with academic, public, and SME participants, organized into focused workpackages to generate and disseminate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre- development to post-marketing surveillance. It aims to develop predictive biomarkers, models of inflammation and autoimmunity, and clinical events classification through a series of clinical trials and population-based studies with parallel pre-clinical models. The consortium has capability in transcriptomics, genotyping, proteomics, metabolomics and data mining, with depth and capacity to discover, validate and distribute novel biomarkers.
More...BioVacSafe is a consortium of vaccine manufacturers together with academic, public, and SME participants, organized into focused workpackages to generate and disseminate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre- development to post-marketing surveillance. It aims to develop predictive biomarkers, models of inflammation and autoimmunity, and clinical events classification through a series of clinical trials and population-based studies with parallel pre-clinical models. The consortium has capability in transcriptomics, genotyping, proteomics, metabolomics and data mining, with depth and capacity to discover, validate and distribute novel biomarkers. A full range of ex vivo and in vivo small animal models of inflammation and biomarker discovery, with advanced immunology and imaging are available.
Less...Accession | PRJNA515032 |
Type | Umbrella project |
Grants | - "Innovative Medicines Initiative Joint Undertaking" (Grant ID 115308, Innovative Medicines Initiative)
|
Submission | Registration date: 14-Jan-2019 BIOVACSAFE- Ghent University
|
Relevance | Medical |
Project Data:
Resource Name | Number of Links |
---|
Sequence data |
SRA Experiments | 2303 |
Publications |
PubMed | 2 |
PMC | 2 |
Other datasets |
BioSample | 2303 |
GEO DataSets | 5 |
GEO Data DetailsParameter | Value |
---|
Data volume, Spots | 258532270 |
Data volume, Processed Mbytes | 5980 |
Data volume, Supplementary Mbytes | 53587 |
SRA Data DetailsParameter | Value |
---|
Data volume, Gbases | 818 |
Data volume, Tbytes | 0.40 |
This project encompasses the following 8 sub-projects:
Project Type | Number of Projects |
Genome sequencingHighest level of assembly : SRA or Trace | 3
|
BioProject accession | Assembly level | Name | Title |
---|
PRJNA492827 | SRA or Trace | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305A | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305A (BIOVACSAFE) | PRJNA492829 | SRA or Trace | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305B | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305B (BIOVACSAFE) | PRJNA492965 | SRA or Trace | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305C | Biomarkers of Vaccine Immunosafety (BioVacSafe) - Study CRC305C (BIOVACSAFE) |
|
Transcriptome or Gene expression | 5 |
BioProject accession | Organism | Title |
---|
PRJNA513089 | Homo sapiens | Gene expression signatures after immunisation with a range of live, inactivated and adjuvanted vaccines (BIOVACSAFE protocols 305A, 305B and 305C) (ICRF, Imperial College London) | PRJNA513088 | Homo sapiens | Gene expression signatures after immunisation with MF59C adjuvanted trivalent inactivated influenza vaccine for season 2014-2015 Northern hemisphere (BIOVACSAFE protocol 305D) (ICRF, Imperial College London) | PRJNA514018 | Homo sapiens | Gene expression signatures after immunisation with Boostrix - alum adsorbed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (BIOVACSAFE protocol 305D2) (ICRF, Imperial College London) | PRJNA513261 | Homo sapiens | Gene expression signatures in blood and muscle biopsy after intramuscular immunization of healthy adult humans with adjuvanted vaccines (BIOVACSAFE protocol 305E) (ICRF, Imperial College London) | PRJNA494386 | Mus musculus | Identification of Biomarkers of Vaccine Reactogenicity (Imperial College London) |
|